Provided by Tiger Fintech (Singapore) Pte. Ltd.

GH Research PLC

10.50
+0.08500.82%
Volume:101.90K
Turnover:1.06M
Market Cap:650.99M
PE:-13.99
High:10.56
Open:10.46
Low:10.00
Close:10.41
Loading ...

BUZZ-GH Research jumps as depression therapy meets mid-stage trial goals

Reuters
·
03 Feb

Top Premarket Gainers

MT Newswires Live
·
03 Feb

GH Research Shares Soar 90% Pre-Bell After Trial of GH001 to Treat Depression Meets All Endpoints

MT Newswires Live
·
03 Feb

GH Research Shares Climb 86.7% Premarket After Depression Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS
·
03 Feb

GH Research announces primary endpoint met in Phase 2b trial of GH001

TIPRANKS
·
03 Feb

GH Research Announces Primary Endpoint Met in Phase 2B Trial With GH001 in Trd Demonstrating -15.5 Point Placebo-Adjusted Madrs Reduction

THOMSON REUTERS
·
03 Feb

GH Research Plc - All Secondary Endpoints Met With Significant Improvements on Day 8

THOMSON REUTERS
·
03 Feb

GH Research Plc - GH001 Well Tolerated With No Serious Adverse Events Reported

THOMSON REUTERS
·
03 Feb

GH Research Shares Rise Ahead of Release of Clinical-Trial Results

Dow Jones
·
01 Feb

GH Research to Provide Update on Phase 2B Trial With GH001 in Trd

THOMSON REUTERS
·
01 Feb

GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Jan

GH Research Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Jan

BUZZ-GH Research rises as lead drug meets main goal in mid-stage studies

Reuters
·
10 Jan

GH Research Plc - Full Response to Ind Hold Planned for Mid-2025

THOMSON REUTERS
·
10 Jan

GH Research Announces Primary Endpoint Met in Two Phase 2a Poc Trials With GH001 and Completion of All FDA Requests to Address Ind Hold With No Findings of Respiratory Toxicity in Non-Rodents

THOMSON REUTERS
·
10 Jan

GH Research Plc - GH001 Well Tolerated With No Treatment-Related Serious Adverse Events

THOMSON REUTERS
·
10 Jan